Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.69 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.69 |
| ▸ | CHRNA2 | Q15822 | 6/20 | 0.69 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.69 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725985 | 1.00 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL2501437 | 0.92 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL4726141 | 0.92 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL4727391 | 0.89 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL2495855 | 0.89 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL13322059 | 0.89 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL6583259 | 0.88 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL6582561 | 0.88 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL16321888 | 0.88 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 | |
| SCHEMBL14941338 | 0.88 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA3CHRNA2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008011484-A2 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA4 4/4885CHRNA3 20/4885 |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | CHRNA5, CHRNA2, CHRNA10 | CHRNB2 7/4885CHRNA4 4/4885CHRNA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.